Bayer bags iPSC specialist BlueRock Therap...Bayer has widened its pipeline in neurology, cardiology, and immunology by acquiring induced pluripotent stem cell specialist BlueRock Therapeutics. more ➔
Liquid biopsy identifies residual breast c...Using a platform tailored to patients’ specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients. more ➔
Novo Holdings puts $72m in LanzatechNovo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the company’s sustainable fuels and chemicals platform more ➔
Google maps for tumours and organsGerman researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy. more ➔
Transgene’s licenced oncolytic virus... SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint … more ➔
Wellington Partners launch €210m Life Sc...Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m. more ➔
Alizé Pharma 3 bags largest EU financing...Venture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3. more ➔
Better TNF? receptor blockers on the horiz...Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments. more ➔
AgroSavfe raises €35m in Series C financ...Plant protection specialist AgroSavfe will use the funds of a €35m Series C financing to push the development, registration and commercial scale production of its biofungicides and bio-insecticide … more ➔
European Commission approves ten GMOs The European Commission has authorised ten genetically modified products. more ➔
